DLC1 suppresses NF-κB activity in prostate cancer cells due to its stabilizing effect on adherens junctions

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-12

  Tripathi, Veenu ^a   Popescu, Nicholas C ^a   Zimonjic, Drazen B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adherens junction (AJ); DLC1; NF kB; Prostate cancer; Rho

Indexed keywords

EID: 84897795404     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-27     Document Type: Article

References (50)

1. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM (2011) Epigenetics in prostate cancer. Prostate Cancer, doi:10.1155/2011/580318.
2. Amit S, Ben-Neriah Y (2003) NF-kappaB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol 13:15-28.
3. Andela VB, Gordon AH, Zotalis G, Rosier RN, Goater JJ, Lewis GD, Schwarz EM, Puzas JE, O'Keefe RJ (2003) NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res 415S:75-85.
4. Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG, Lowy DR (2010) E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene 29:2760-2771.
5. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101:10137-10142.
6. Boyer L, Travaglione S, Falzano L, Gauthier NC, Popoff MR, Lemichez E, Fiorentini C, Fabbri A (2004) Rac GTPase instructs nuclear factor-kappaB activation by conveying the SCF complex and IkBalpha to the ruffling membranes. Mol Biol Cell 15:1124-1133.
7. Cammarano MS, Minden A (2001) Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem 276:25876-25882.
8. Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20:7342-7351.
9. Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, Curley SA (2002) Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 95:1696-1705.
10. Crépieux P, Kwon H, Leclerc N, Spencer W, Richard S, Lin R, Hiscott J (1997) I kappaB alpha physically interacts with a cytoskeleton-associated protein through its signal response domain. Mol Cell Biol 17:7375-7385.
11. Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, Hung MC (2002) beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2(4):323-334.
12. Durkin ME, Yuan BZ, Zhou X, Zimonjic DB, Lowy DR, Thorgeirsson SS, Popescu NC (2007) DLC-1:a Rho GTPase-activating protein and tumour suppressor. J Cell Mol Med 11:1185-1207.
13. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115:141-151.
14. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-S96.
15. Gnad R, Kaina B, Fritz G (2001) Rho GTPases are involved in the regulation of NF-kappaB by genotoxic stress. Exp Cell Res 264:244-249.
16. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC (2006) Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res 12:1412-1419.
17. Guan M, Tripathi V, Zhou X, Popescu NC (2008) Adenovirus-mediated restoration of expression of the tumor suppressor gene DLC1 inhibits the proliferation and tumorigenicity of aggressive, androgen-independent human prostate cancer cell lines: prospects for gene therapy. Cancer Gene Ther 15:371-381.
18. Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, Din M, Mukhtar H (2008) A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling. Cancer Res 68:8564-8572.
19. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF (2003) Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 63:1359-1364.
20. Hoffmann A, Leung TH, Baltimore D (2003) Genetic analysis of NFkappaB/Rel transcription factors defines functional specificities. EMBO J 22:5530-5539.
21. Hsieh CL, Oakley-Girvan I, Balise RR, Halpern J, Gallagher RP, Wu AH, Kolonel LN, O'Brien LE, Lin IG, Van Den Berg DJ, Teh CZ, West DW, Whittemore AS (2001) A genome screen of families with multiple cases of prostate cancer: evidence of genetic heterogeneity. Am J Hum Genet 69:148-158.
22. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197.
23. Huber MA, Azoitei N, Baumann B, Grünert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T (2004) NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 114:569-581.
24. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, Dargemont C, de Herreros AG, Bellacosa A, Larue L (2007) Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26:7445-7456.
25. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2:301-310.
26. Kobielak A, Fuchs E (2006) Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci U S A 103:2322-2327.
27. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK (2004) Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene 23:8509-8519.
28. Lien WH, Klezovitch O, Fernandez TE, Delrow J, Vasioukhin V (2006) alphaE-catenin controls cerebral cortical size by regulating the hedgehog signaling pathway. Science 311:1609-1612.
29. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT (2007) Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13:78-83.
30. Luo JL, Kamata H, Karin M (2005) IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 115:2625-2632.
31. Matsuyama H, Pan Y, Oba K, Yoshihiro S, Matsuda K, Hägarth L, Kudren D, Naito K, Bergerheim USR, Ekman P (2001) Deletions on chromosome 8p22 may predict disease progression as well as pathological staging in prostate cancer. Clin Cancer Res 7:3139-3143.
32. Pajonk F, Pajonk K, McBride WH (1999) Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst 91:1956-1960.
33. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 18:7389-7394.
34. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY (2007) NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13:62-69.
35. Perona R, Montaner S, Saniger L, Sánchez-Pérez I, Bravo R, Lacal JC (1997) Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev 11:463-475.
36. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, Neville LA, Potter KN, Mann J, Mann DA, Johnson PW, Stevenson FK, Packham G (2007) Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26:1166-1177.
37. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466.
38. Segain JP, Raingeard de la Blétière D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP, Loirand G (2003) Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 124:1180-1187.
39. Shih YP, Liao YC, Lin Y, Lo SH (2010) DLC1 negatively regulates angiogenesis in a paracrine fashion. Cancer Res 70:8270-8275.
40. Solanas G, Porta-de-la-Riva M, Agustí C, Casagolda D, Sánchez-Aguilera F, Larriba MJ, Pons F, Peiró S, Escrivà M, Muñoz A, Duñach M, de Herreros AG, Baulida J (2008) E-cadherin controls beta-catenin and NF-kappaB transcriptional activity in mesenchymal gene expression. J Cell Sci 121:2224-2234.
41. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gélinas C, Rabson AB (2002) Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 52:183-200.
42. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10:5501-5507.
43. Tapia MA, González-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, Ross JS, Mezquita J, Mezquita C, Bachs O, Gascón P, Rojo F, Perona R, Rovira A, Albanell J (2007) Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6:2284-2292.
44. Tripathi V, Popescu NC, Zimonjic DB (2012) DLC1 interaction with α-catenin stabilizes adherens junctions and enhances DLC1 antioncogenic activity. Mol Cell Biol 32:2145-2159.
45. Tripathi V, Popescu NC, Zimonjic DB (2013) DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion. Oncogene, doi: 10.1038/onc.2013.7.
46. Ullmannova-Benson V, Guan M, Zhou X, Tripathi V, Yang XY, Zimonjic DB, Popescu NC (2009) DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. Leukemia 23:383-390.
47. Wheelock MJ, Johnson KR (2003) Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol 19:207-235.
48. Wilson KF, Erickson JW, Antonyak MA, Cerione RA (2013) Rho GTPases and their roles in cancer metabolism. Trends Mol Med 19:74-82.
49. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, Sterling D, Lange EM, Hawkins GA, Turner A, Ewing CM, Faith DA, Johnson JR, Suzuki H, Bujnovszky P, Wiley KE, DeMarzo AM, Bova GS, Chang B, Hall MC, McCullough DL, Partin AW, Kassabian VS, Carpten JD, Bailey-Wilson JE, Trent JM, Ohar J, Bleecker ER, Walsh PC, Isaacs WB, Meyers DA (2002) Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 32:321-325.
50. Zimonjic DB, Popecu NC (2012) Role of DLC1 tumor suppressor gene and Myc oncogene in pathogenesis of hujman hepatocellular carcinoma: potential prospects for combined targeted therapeutics. Int J Oncology 41:393-406.